Baptist Cancer Services offers patients participation in clinical trials. Following are the clinical trials currently available. For more information, contact our Baptist Cancer Services Navigator, Tonya Ball, at 601-974-6238. (Updated 3/18/2016)
Merrimack - MM302 with Herceptin in advanced metastatic breast cancer
Novartis - Randomized study of Ribociclib in combination with Faslodex for advanced breast cancer
Puma Biotechnology - Neratinib plus Xeloda versus Tykerb plus Xeloda in patients with HER 2 positive metastatic breast cancer who have received two or more regimens for metastatic disease
Genentech -Expanded Access program for patients with locally advanced or metastatic urothelial carcinoma after progression on a platinum chemotherapy regimen
Pharmacyclics -Observational registry of CLL patients designed to describe treatment patterns and assess patient's quality of life
Astellas - Randomized phase 3 study of ASP8273 vs. Erlotinib in first- line treatment of advanced NSCLC with EGFR mutations
BMS - Nivolumab in advanced NSCLC as maintenance after induction chemotherapy or as first line treatment with standard of care regimens
Baptist has partnered with Conversant Bio to participate in an observational study. Conversant Bio’s work involves using biospecimens obtained during scheduled procedures. These biospecimens include blood taken at the same time blood is drawn for physician ordered tests and/or unused tissue from a surgical procedure that is not needed for diagnosis or treatment. The biospecimens obtained are sent to researchers who work with all disease types. Participation may assist these researchers in developing new treatments or improving procedures for detecting diseases. There is no increased risk to participate and participation is strictly voluntary.
What can we help you find?